斯普林注射液在中晚期肺癌综合治疗中的作用

Role of sipulin injection in comprehensive treatment of lung cancer in medium and terminal stages

目的观察斯普林注射液配合放、化疗治疗中晚期肺癌的疗效。方法将147例中晚期肺癌患者随机分为斯普林注射液配合放、化疗组(治疗组,75例),单纯放、化疗组(对照组,72例),两组放、化疗方法相同,治疗组在放、化疗开始即给予斯普林10mL,加入0.9%氯化钠注射液250mL中静滴,连用14d,21d为1周期,共4～6周期,对多个临床指标进行比较观察。结果治疗组近期疗效为60.0%,对照组为48.6%,两组无统计学差异(P>0.05)。治疗组1、2年生存率分别为58.9%、41.1%,对照组分别为42.3%、25.4%,两组有统计学差异(P<0.05)。治疗组患者的生活质量、治疗后T细胞亚群及NK细胞活性明显高于对照组,血液学各项指标下降程度、消化道不良反应及放射性食管炎均明显轻于对照组,两组有统计学差异(P<0.05)。结论斯普林注射液用于配合放、化疗治疗中晚期肺癌有一定疗效。

Objective To observe the clinical effects of sipulin combined with radiotherapy and chemotherapy.Methods 147 patients were randomly divided into 2 groups：the sipulin group was treated with sipulin combined with radiotherapy and chemotherapy（n=75） and the control group was only treated with radiotherapy and chemotherapy（n=72）.The methods of radiotherapy and chemotherapy were identical in the two groups.The sipulin group received intravenous infusions of sipulin（10 mL in 250 mL 0.9% NS） for 14 days,4-6 cycles（21days in one cycle）.The clinical indexes were observed and analyzed.Results The efficiency rate was 60.0% in the sipulin group and 48.6% in the control group,and there was no significant difference between the two groups（P〉0.05）.The 1-and 2-year survival rates in the sipulin group（58.9% and 41.1%）were significantly higher than those in the control group（42.3% and 25.4%）（P〈0.05）.The quality of life and the counts of T and NK cells after treatment in the sipulin group were significantly increased.The decline of the hematocyte count,the side effect of the alimentary tract and radioesophagitis were evidently reduced in the sipulin group compared with the control group.Conclusion Sipulin injection is effective and safe as an adjuvant in radiotherapy and chemotherapy for lung cancer in medium and terminal stages.